<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314636</url>
  </required_header>
  <id_info>
    <org_study_id>NMSG25/16</org_study_id>
    <nct_id>NCT03314636</nct_id>
  </id_info>
  <brief_title>Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.</brief_title>
  <acronym>CONPET</acronym>
  <official_title>KRd Consolidation in Myeloma Patients With a Positive PET-CT After Standard First Line Treatment. A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Myeloma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A PET-CT will be performed on patients with myeloma after a standard first-line treatment.
      The PET-positive patients will receive 4 cycles of Carfilzomb-Revlimid-Dexamethason (KRd),
      before a new PET-CT will be performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be evaluated for inclusion after finishing first-line therapy, or after a
      sufficient amount of treatment in first-line, and a sufficient respons (VGPR). Eligible
      performed regimens are defined in the protocol. All patients will perform a PET-CT, and
      PET-negative patients will be excluded from protocol treatment. The PET-positive patients
      will do a minimal residual disease (MRD-)evaluation in the bone marrow before entering
      treatment. After 4 28day cycles of Carfilzomib-Revlimid-Dexamethason, a new MRD and a new
      PET-CT will be performed, as measures of outcome. Patients will continue treatment as written
      in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET negativity after induction</measure>
    <time_frame>1 month after induction</time_frame>
    <description>How many of PET positive patients will become PET negative after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PET correlation with MRD Euroflow</measure>
    <time_frame>1 month after induction</time_frame>
    <description>Before intervention all patients are PET-CT positive. The investigators will measure minimal residual disease (MRD) with immuno-flow cytometry, at the same timepoint, and describe how many of the PET-CT patients, are MRD-negative and how many are MRD-positive. After the intervention the investigators will again do PET-CT and MRD by flow cytometry. The investigators will then describe how many PET-positive patients are MRD-positive and how many are MRD-negative. As well, the investigators will describe the same in the PET-CT negative patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>PET-CT-positive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib 20/36mg/m2 days 1,2,8,9,15,16 Lenalidomide 25mg days 1-21 Dexamethasone 40mg days 1,8,15,22 28 day cycles 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>See in arm description</description>
    <arm_group_label>PET-CT-positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>See in arm description</description>
    <arm_group_label>PET-CT-positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET-CT</intervention_name>
    <description>See in arm description</description>
    <arm_group_label>PET-CT-positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>See in arm description</description>
    <arm_group_label>PET-CT-positive patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Prior confirmed diagnosis of multiple myeloma (2014).

          2. Received standard first line treatment with at least partial response. Standard first
             line treatment is defined as

               -  VRD, VTD or VCD followed by ASCT, or

               -  MPV at least 6 cycles, or no further reduction in monoclonal component the last 2
                  cycles, or

               -  Rd at least 9 cycles or no further reduction in monoclonal component the last 2
                  cycles.

          3. Carfilzomib naïve.

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          5. Absolute neutrophil count (ANC) ≥ 0,5 x 109/L) and platelet count &gt;35 x 109/L.

          6. At least very good partial remission (VGPR) from first line treatment

        Exclusion Criteria:

          1. Change of first line treatment because of stabile or progressive disease.

          2. Major surgery within 28 days before enrollment.

          3. Radiotherapy within 14 days before enrollment, but if the involved field is small, 7
             days will be considered a sufficient interval before onset of the treatment.

          4. Glucocorticoid therapy within the 14 days prior to inclusion that exceeds a cumulative
             dose of 160 mg dexamethasone or 1000 mg prednisone.

          5. Central nervous system involvement.

          6. Uncontrolled heart disease, including congestive heart failure (NYHA III-IV),
             uncontrolled angina pectoris, uncontrolled conduction abnormalities, acute diffuse
             infiltrative pulmonary disease, pericardial disease or myocardial infarction within 6
             months prior to enrollment

          7. Uncontrolled hypertension or uncontrolled diabetes despite medication

          8. Active hepatitis B or C infection or known human immunodeficiency virus (HIV)
             positivity.

          9. Another active malignancy. Patients with non-melanoma skin cancer or carcinoma in situ
             of any type are not excluded if they have undergone complete resection.

         10. Primary plasma cell leukemia, systemic AL amyloidosis, Waldenströms macroglobulinemia,
             POEMS syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fredrik H Schjesvold, MD PhD</last_name>
    <phone>+4799697796</phone>
    <email>fredrikschjesvold@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Lysén, MSc</last_name>
    <phone>+4747246569</phone>
    <email>annaly@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Abildgaard</last_name>
      <email>Niels.Abildgaard@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fredrik H Schjesvold, MDPhD</last_name>
      <phone>+4799697796</phone>
      <email>fredrikschjesvold@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markus Hansson</last_name>
      <email>markus.hansson@med.lu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>October 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Fredrik Hellem Schjesvold</investigator_full_name>
    <investigator_title>Head of Oslo Myeloma Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

